NEO
NeoGenomics, Inc.
Medical - Diagnostics & Research
Market Cap$290M
5Y Perf.-64.0%
Build Your Comparison
Side-by-side financial analysisNEO
CDNA
JPM
Try popular comparisons:
Stock Comparison
NEO vs CDNA vs JPM
Revenue, margins, valuation, and 5-year total return — side by side.
CDNA
CareDx, Inc
Medical - Diagnostics & Research
Market Cap$1.19B
5Y Perf.-35.2%
JPM
JPMorgan Chase & Co.
Banks - Diversified
Market Cap$896.00B
5Y Perf.+241.0%
NEO vs CDNA vs JPM — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  NEO |  CDNA |  JPM |
|---|---|---|---|
| Industry | Medical - Diagnostics & Research | Medical - Diagnostics & Research | Banks - Diversified |
| Market Cap | $290M | $1.19B | $896.00B |
| Revenue (TTM) | $746M | $413M | $280.33B |
| Net Income (TTM) | $-99M | $-8M | $57.05B |
| Gross Margin | 42.1% | 48.2% | 60.0% |
| Operating Margin | -13.9% | -3.3% | 25.9% |
| Forward P/E | 61.9x | 24.6x | 14.4x |
| Total Debt | $472M | $20M | $942.38B |
| Cash & Equiv. | $160M | $65M | $343.34B |
NEO vs CDNA vs JPM — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
NEO
CDNA
JPM
| Stock | Jun 20 | Jun 26 | Return |
|---|---|---|---|
| NeoGenomics, Inc. (NEO) | 100 | 36.0 | -64.0% |
| CareDx, Inc (CDNA) | 100 | 64.8 | -35.2% |
| JPMorgan Chase & Co. (JPM) | 100 | 341.0 | +241.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: NEO vs CDNA vs JPM
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: JPM leads in 5 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. NeoGenomics, Inc. is the stronger pick specifically for recent price momentum and sentiment. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
🥇JPM emerged as the overall leader. Track its performance:
NEO
NeoGenomics, Inc.
The Growth Play
NEO is the clearest fit if your priority is growth exposure.
- Rev growth 10.1%, EPS growth -35.5%, 3Y rev CAGR 12.6%
- +50.9% vs JPM's +21.8%
Best for: growth exposure
CDNA
CareDx, Inc
The Defensive Pick
CDNA is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 1.17, Low D/E 6.5%, current ratio 2.86x
- 13.8% revenue growth vs JPM's 3.3%
Best for: sleep-well-at-night
JPM
JPMorgan Chase & Co.
The Banking Pick
JPM carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 15 yrs, beta 0.94, yield 1.9%
- 465.8% 10Y total return vs CDNA's 388.7%
- Beta 0.94, yield 1.9%, current ratio 0.52x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  CDNA | 13.8% revenue growth vs JPM's 3.3% |
| Value |  JPM | Lower P/E (14.4x vs 24.6x) |
| Quality / Margins | JPM | 20.4% margin vs NEO's -13.3% |
| Stability / Safety | JPM | Beta 0.94 vs NEO's 1.37 |
| Dividends | JPM | 1.9% yield; 15-year raise streak; the other 2 pay no meaningful dividend |
| Momentum (1Y) |  NEO | +50.9% vs JPM's +21.8% |
| Efficiency (ROA) | JPM | 1.3% ROA vs NEO's -7.2%, ROIC 4.5% vs -4.3% |
NEO vs CDNA vs JPM — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2025
FY 2025
NEO vs CDNA vs JPM — Financial Metrics
Side-by-side numbers across 3 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLJPMLAGGINGNEO
NEONeoGenomics, Inc.
0leads
CDNACareDx, Inc
1leads
JPMJPMorgan Chase & Co.
4leads
6 Total Categories
CATEGORYLEADERvs CDNAvs NEOMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
JPM4/6
Valuation MetricsMultiples, price ratios, and targets
JPM3/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
JPM5/8
Total Returns1Y, 3Y, 5Y total returns with dividends
CDNA3/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
JPM1/1
Income & Cash Flow (Last 12 Months)
JPM leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
JPM is the larger business by revenue, generating $280.3B annually — 679.1x CDNA's $413M. JPM is the more profitable business, keeping 20.4% of every revenue dollar as net income compared to NEO's -13.3%. On growth, CDNA holds the edge at +39.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | NEONeoGenomics, Inc. | CDNACareDx, Inc | JPMJPMorgan Chase & … |
|---|---|---|---|
| RevenueTrailing 12 months | $746M | $413M | $280.3B |
| EBITDAEarnings before interest/tax | -$54M | $2M | $81.4B |
| Net IncomeAfter-tax profit | -$99M | -$8M | $57.0B |
| Free Cash FlowCash after capex | -$5M | $65M | $100.9B |
| Gross MarginGross profit ÷ Revenue | +42.1% | +48.2% | +60.0% |
| Operating MarginEBIT ÷ Revenue | -13.9% | -3.3% | +25.9% |
| Net MarginNet income ÷ Revenue | -13.3% | -2.0% | +20.4% |
| FCF MarginFCF ÷ Revenue | -0.7% | +15.8% | +36.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | +11.1% | +39.0% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +35.0% | +126.3% | +16.0% |
JPM leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
JPM leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, JPM's 18.4x EV/EBITDA is more attractive than NEO's 345.5x.
| Metric | NEONeoGenomics, Inc. | CDNACareDx, Inc | JPMJPMorgan Chase & … |
|---|---|---|---|
| Market CapShares × price | $290M | $1.2B | $896.0B |
| Enterprise ValueMkt cap + debt − cash | $603M | $1.1B | $1.50T |
| Trailing P/EPrice ÷ TTM EPS | -2.65x | -57.42x | 16.00x |
| Forward P/EPrice ÷ next-FY EPS est. | 61.94x | 24.59x | 14.40x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 0.90x |
| EV / EBITDAEnterprise value multiple | 345.49x | — | 18.36x |
| Price / SalesMarket cap ÷ Revenue | 0.40x | 3.12x | 3.20x |
| Price / BookPrice ÷ Book value/share | 0.34x | 4.04x | 2.47x |
| Price / FCFMarket cap ÷ FCF | — | 32.85x | 8.88x |
JPM leads this category, winning 3 of 6 comparable metrics.
Profitability & Efficiency
JPM leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
JPM delivers a 15.9% return on equity — every $100 of shareholder capital generates $16 in annual profit, vs $-12 for NEO. CDNA carries lower financial leverage with a 0.06x debt-to-equity ratio, signaling a more conservative balance sheet compared to JPM's 2.60x.
| Metric | NEONeoGenomics, Inc. | CDNACareDx, Inc | JPMJPMorgan Chase & … |
|---|---|---|---|
| ROE (TTM)Return on equity | -11.8% | -2.6% | +15.9% |
| ROA (TTM)Return on assets | -7.2% | -1.9% | +1.3% |
| ROICReturn on invested capital | -4.3% | -5.7% | +4.5% |
| ROCEReturn on capital employed | -5.1% | -5.8% | +8.9% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 5 | 5 |
| Debt / EquityFinancial leverage | 0.56x | 0.06x | 2.60x |
| Net DebtTotal debt minus cash | $313M | -$46M | $599.0B |
| Cash & Equiv.Liquid assets | $160M | $65M | $343.3B |
| Total DebtShort + long-term debt | $472M | $20M | $942.4B |
| Interest CoverageEBIT ÷ Interest expense | -30.15x | — | 0.74x |
JPM leads this category, winning 5 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
CDNA leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in JPM five years ago would be worth $21,820 today (with dividends reinvested), compared to $2,538 for CDNA. Over the past 12 months, NEO leads with a +50.9% total return vs JPM's +21.8%. The 3-year compound annual growth rate (CAGR) favors CDNA at 40.4% vs NEO's -11.6% — a key indicator of consistent wealth creation.
| Metric | NEONeoGenomics, Inc. | CDNACareDx, Inc | JPMJPMorgan Chase & … |
|---|---|---|---|
| YTD ReturnYear-to-date | -5.2% | +20.0% | -0.5% |
| 1-Year ReturnPast 12 months | +50.9% | +22.0% | +21.8% |
| 3-Year ReturnCumulative with dividends | -31.0% | +176.7% | +138.2% |
| 5-Year ReturnCumulative with dividends | -74.4% | -74.6% | +118.2% |
| 10-Year ReturnCumulative with dividends | +42.1% | +388.7% | +465.8% |
| CAGR (3Y)Annualised 3-year return | -11.6% | +40.4% | +33.6% |
CDNA leads this category, winning 3 of 6 comparable metrics.
Risk & Volatility
Evenly matched — CDNA and JPM each lead in 1 of 2 comparable metrics.
Risk & Volatility
JPM is the less volatile stock with a 0.94 beta — it tends to amplify market swings less than NEO's 1.37 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CDNA currently trades 95.2% from its 52-week high vs NEO's 81.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | NEONeoGenomics, Inc. | CDNACareDx, Inc | JPMJPMorgan Chase & … |
|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.37x | 1.17x | 0.94x |
| 52-Week HighHighest price in past year | $13.74 | $24.13 | $337.25 |
| 52-Week LowLowest price in past year | $4.72 | $10.96 | $262.71 |
| % of 52W HighCurrent price vs 52-week peak | +81.1% | +95.2% | +95.1% |
| RSI (14)Momentum oscillator 0–100 | 70.8 | 64.3 | 59.1 |
| Avg Volume (50D)Average daily shares traded | 1.9M | 694K | 7.0M |
Evenly matched — CDNA and JPM each lead in 1 of 2 comparable metrics.
Analyst Outlook
JPM leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: NEO as "Buy", CDNA as "Buy", JPM as "Buy". Consensus price targets imply 70.4% upside for NEO (target: $19) vs 4.5% for CDNA (target: $24). JPM is the only dividend payer here at 1.86% yield — a key consideration for income-focused portfolios.
| Metric | NEONeoGenomics, Inc. | CDNACareDx, Inc | JPMJPMorgan Chase & … |
|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $19.00 | $24.00 | $339.75 |
| # AnalystsCovering analysts | 29 | 13 | 61 |
| Dividend YieldAnnual dividend ÷ price | — | — | +1.9% |
| Dividend StreakConsecutive years of raises | 0 | — | 15 |
| Dividend / ShareAnnual DPS | — | — | $5.95 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +7.4% | +3.9% |
JPM leads this category, winning 1 of 1 comparable metric.
Key Takeaway
JPM leads in 4 of 6 categories (Income & Cash Flow, Valuation Metrics). CDNA leads in 1 (Total Returns). 1 tied.
Best OverallJPMorgan Chase & Co. (JPM)Leads 4 of 6 categories
Loading custom metrics...
NEO vs CDNA vs JPM: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is NEO or CDNA or JPM a better buy right now?
For growth investors, CareDx, Inc (CDNA) is the stronger pick with 13.
8% revenue growth year-over-year, versus 3. 3% for JPMorgan Chase & Co. (JPM). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 0x trailing P/E (14. 4x forward), making it the more compelling value choice. Analysts rate NeoGenomics, Inc. (NEO) a "Buy" — based on 29 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — NEO or CDNA or JPM?
On forward P/E, JPMorgan Chase & Co.
is actually cheaper at 14. 4x.
03Which is the better long-term investment — NEO or CDNA or JPM?
Over the past 5 years, JPMorgan Chase & Co.
(JPM) delivered a total return of +118. 2%, compared to -74. 6% for CareDx, Inc (CDNA). Over 10 years, the gap is even starker: JPM returned +465. 8% versus NEO's +42. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — NEO or CDNA or JPM?
By beta (market sensitivity over 5 years), JPMorgan Chase & Co.
(JPM) is the lower-risk stock at 0. 94β versus NeoGenomics, Inc. 's 1. 37β — meaning NEO is approximately 45% more volatile than JPM relative to the S&P 500. On balance sheet safety, CareDx, Inc (CDNA) carries a lower debt/equity ratio of 6% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.
05Which is growing faster — NEO or CDNA or JPM?
By revenue growth (latest reported year), CareDx, Inc (CDNA) is pulling ahead at 13.
8% versus 3. 3% for JPMorgan Chase & Co. (JPM). On earnings-per-share growth, the picture is similar: JPMorgan Chase & Co. grew EPS 1. 5% year-over-year, compared to -143. 0% for CareDx, Inc. Over a 3-year CAGR, NEO leads at 12. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — NEO or CDNA or JPM?
JPMorgan Chase & Co.
(JPM) is the more profitable company, earning 20. 4% net margin versus -14. 9% for NeoGenomics, Inc. — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus -9. 1% for NEO. At the gross margin level — before operating expenses — CDNA leads at 67. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is NEO or CDNA or JPM more undervalued right now?
On forward earnings alone, JPMorgan Chase & Co.
(JPM) trades at 14. 4x forward P/E versus 61. 9x for NeoGenomics, Inc. — 47. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NEO: 70. 4% to $19. 00.
08Which pays a better dividend — NEO or CDNA or JPM?
In this comparison, JPM (1.
9% yield) pays a dividend. NEO, CDNA do not pay a meaningful dividend and should not be held primarily for income.
09Is NEO or CDNA or JPM better for a retirement portfolio?
For long-horizon retirement investors, JPMorgan Chase & Co.
(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 94), 1. 9% yield, +465. 8% 10Y return). Both have compounded well over 10 years (JPM: +465. 8%, NEO: +42. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between NEO and CDNA and JPM?
These companies operate in different sectors (NEO (Healthcare) and CDNA (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: NEO is a small-cap quality compounder stock; CDNA is a small-cap quality compounder stock; JPM is a large-cap deep-value stock. JPM pays a dividend while NEO, CDNA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.